Arcturus Therapeutics Holdings Total Assets 2011-2026 | ARCT

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Arcturus Therapeutics Holdings

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
271 M	344 M	429 M	450 M	393 M	476 M	82.1 M	44.2 M	52 M	51.6 M	71.7 M	22.3 M	50.3 M	201 K	1.2 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
476 M	201 K	183 M

Quarterly Total Assets Arcturus Therapeutics Holdings

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
282 M	309 M	344 M	371 M	389 M	419 M	429 M	458 M	431 M	471 M	450 M	294 M	337 M	342 M	393 M	435 M	449 M	481 M	476 M	476 M	476 M	476 M	82.1 M	82.1 M	82.1 M	82.1 M	44.2 M	44.2 M	44.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
481 M	44.2 M	326 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Autolus Therapeutics plc AUTL	589 M	$ 1.38	-1.08 %	$ 367 M	Britain
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
DBV Technologies S.A. DBVT	234 M	$ 20.52	0.79 %	$ 2.86 B	France
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.72	3.24 %	$ 8.95 B	Australia
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Aytu BioScience AYTU	124 M	$ 2.57	-3.48 %	$ 16.1 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Forte Biosciences FBRX	82.8 M	$ 26.92	1.8 %	$ 349 M	USA
Fennec Pharmaceuticals FENC	70.6 M	$ 6.22	-3.12 %	$ 178 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Fulcrum Therapeutics FULC	366 M	$ 7.72	-1.4 %	$ 489 K	USA
Galectin Therapeutics GALT	19.5 M	$ 2.24	-12.55 %	$ 143 M	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Gilead Sciences GILD	59 B	$ 138.79	-0.96 %	$ 173 B	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Galmed Pharmaceuticals Ltd. GLMD	18.5 M	$ 0.56	8.45 %	$ 521 K	Israel
Genmab A/S GMAB	21.1 B	$ 27.26	-1.77 %	$ 17.2 B	Danmark
Gossamer Bio GOSS	172 M	$ 0.32	-7.03 %	$ 73.1 M	USA
Grifols, S.A. GRFS	21.4 B	$ 8.02	-2.55 %	$ 6.83 B	Spain
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
GT Biopharma GTBP	8.11 M	$ 0.41	-7.26 %	$ 2.26 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
BioNTech SE BNTX	22 B	$ 88.74	-2.78 %	$ 27.2 B	Germany
Halozyme Therapeutics HALO	2.53 B	$ 63.49	0.64 %	$ 7.61 B	USA
Coherus BioSciences CHRS	258 M	$ 1.62	-3.1 %	$ 190 M	USA
Akari Therapeutics, Plc AKTX	47.9 M	$ 3.32	-6.21 %	$ 224 B	Britain
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	4.97 B	$ 318.56	-3.57 %	$ 41.7 B	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Harmony Biosciences Holdings HRMY	1.27 B	$ 27.62	-0.34 %	$ 1.59 B	USA
Aileron Therapeutics ALRN	24.2 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
iBio IBIO	23.2 M	$ 2.08	2.47 %	$ 21.8 M	USA
ImmuCell Corporation ICCC	42.5 M	$ 6.54	-1.06 %	$ 59 M	USA
InflaRx N.V. IFRX	55.2 M	$ 0.99	4.91 %	$ 152 M	Germany
Burford Capital Limited BUR	3.11 B	$ 4.46	-0.45 %	$ 729 M	Britain
Immutep Limited IMMP	157 M	$ 0.35	-3.58 %	$ 1.08 B	Australia